DDrare: Database of Drug Development for Rare Diseases

Hmpl004-6599 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03597971 (ClinicalTrials.gov)	March 20, 2018	3/5/2018	HMPL004-6599 Phase I Dose-escalating Study	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL004-6599 in Healthy Male Volunteers	Ulcerative Colitis;Crohn Disease	Drug: HMPL004-6599;Drug: Placebo	Nutrition Science Partners Limited	Hutchison Medipharma Limited;Nestlé	Terminated	18 Years	45 Years	Male	32	Phase 1	Australia

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03597971 (ClinicalTrials.gov)	March 20, 2018	3/5/2018	HMPL004-6599 Phase I Dose-escalating Study	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL004-6599 in Healthy Male Volunteers	Ulcerative Colitis;Crohn Disease	Drug: HMPL004-6599;Drug: Placebo	Nutrition Science Partners Limited	Hutchison Medipharma Limited;Nestlé	Terminated	18 Years	45 Years	Male	32	Phase 1	Australia